NATERA, INC. (NTRA) Spending and interest coverage
- R&D / revenue · 12 months: Value 29.09%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 14.09%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 29.09% | Research and development expense / revenue. Period ending 2026-06-30. $787.38M ÷ $2.71B × 100 ≈ 29.09% |
| Stock-based compensation / revenue · 12 months | 14.09% | Share-based compensation / revenue. Period ending 2026-06-30. $381.42M ÷ $2.71B × 100 ≈ 14.09% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 787.38M USD | Research and Development Expense |
| Revenue | 2.71B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 381.42M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -289.67M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $787.38M | $2.71B | $381.42M | $-289.67M | (m) | 29.09% | 14.09% | (m) | (m) |
| 2026-03-31 | $705.73M | $2.50B | $371.68M | $-324.25M | (m) | 28.22% | 14.86% | (m) | (m) |
| 2025-12-31 | $624.11M | $2.31B | $354.40M | $-309.91M | $4.07M | 27.06% | 15.37% | -76.16× | Reported |
| 2025-09-30 | $578.38M | $2.12B | $333.75M | $-351.87M | $4.37M | 27.32% | 15.77% | -80.52× | Reported |
| 2025-06-30 | $501.90M | $1.96B | $313.75M | $-293.63M | $6.47M | 25.55% | 15.97% | -45.40× | Reported |
| 2025-03-31 | $444.58M | $1.83B | $287.81M | $-227.16M | $8.57M | 24.28% | 15.72% | -26.52× | Reported |
| 2024-12-31 | $404.14M | $1.70B | $274.43M | $-222.29M | $10.69M | 23.82% | 16.17% | -20.80× | Reported |
| 2024-09-30 | $357.64M | $1.53B | $251.93M | $-242.09M | $12.54M | 23.35% | 16.45% | -19.30× | Reported |
| 2024-06-30 | $337.94M | $1.36B | $238.88M | $-313.73M | $12.65M | 24.84% | 17.56% | -24.80× | Reported |
| 2024-03-31 | $327.01M | $1.21B | $215.78M | $-382.26M | $12.70M | 27.06% | 17.85% | -30.10× | Reported |
| 2023-12-31 | $320.68M | $1.08B | $191.81M | $-446.25M | $12.64M | 29.62% | 17.72% | -35.31× | Reported |
| 2023-09-30 | $325.63M | $988.72M | $178.88M | $-503.48M | $12.24M | 32.93% | 18.09% | -41.13× | Reported |
| 2023-06-30 | $313.90M | $931.05M | $161.49M | $-511.55M | $11.32M | 33.71% | 17.34% | -45.19× | Reported |
| 2023-03-31 | $318.31M | $867.85M | $157.99M | $-542.21M | $10.29M | 36.68% | 18.21% | -52.68× | Reported |
| 2022-12-31 | $316.42M | $820.22M | $152.38M | $-541.04M | $9.32M | 38.58% | 18.58% | -58.06× | Reported |
| 2022-09-30 | $300.31M | $776.00M | $146.82M | $-538.93M | $8.65M | 38.70% | 18.92% | -62.33× | Reported |
| 2022-06-30 | $333.26M | $723.48M | $132.94M | $-570.08M | $8.39M | 46.06% | 18.38% | -67.91× | Reported |
| 2022-03-31 | $304.43M | $667.30M | $127.07M | $-542.29M | $8.32M | 45.62% | 19.04% | -65.19× | Reported |
| 2021-12-31 | $264.21M | $625.49M | $115.22M | $-468.17M | $8.30M | 42.24% | 18.42% | -56.37× | Reported |
| 2021-09-30 | $224.78M | $564.84M | $100.56M | $-402.48M | $10.54M | 39.80% | 17.80% | -38.20× | Reported |
| 2021-06-30 | $152.75M | $504.86M | $89.13M | $-308.06M | $12.73M | 30.25% | 17.65% | -24.20× | Reported |
| 2021-03-31 | $122.00M | $449.31M | $65.99M | $-244.42M | $14.69M | 27.15% | 14.69% | -16.64× | Reported |
| 2020-12-31 | $100.03M | $391.00M | $50.17M | $-216.28M | $15.08M | 25.58% | 12.83% | -14.34× | Reported |
| 2020-09-30 | $82.65M | $361.87M | $42.93M | $-177.12M | $13.35M | 22.84% | 11.86% | -13.27× | Reported |
| 2020-06-30 | $69.03M | $341.63M | $38.14M | $-142.44M | $11.75M | 20.21% | 11.16% | -12.12× | Reported |
| 2020-03-31 | $58.15M | $329.52M | $31.99M | $-119.41M | $10.43M | 17.65% | 9.71% | -11.45× | Reported |
| 2019-12-31 | $51.36M | $302.33M | $28.62M | $-116.29M | $10.69M | 16.99% | 9.47% | -10.88× | Reported |
| 2019-09-30 | $49.13M | $286.05M | $24.16M | $-111.20M | $10.86M | 17.17% | 8.45% | -10.24× | Reported |
| 2019-06-30 | $48.72M | $273.42M | $17.53M | $-117.28M | $10.97M | 17.82% | 6.41% | -10.69× | Reported |
| 2019-03-31 | $48.45M | $262.14M | $15.10M | $-115.86M | $10.81M | 18.48% | 5.76% | -10.72× | Reported |
| 2018-12-31 | $51.35M | $257.65M | $14.20M | $-114.63M | $10.48M | 19.93% | 5.51% | -10.94× | Reported |
| 2018-09-30 | $51.60M | $244.05M | $13.13M | $-130.22M | $10.06M | 21.14% | 5.38% | -12.94× | Reported |
| 2018-06-30 | $51.82M | $234.68M | $12.50M | $-128.84M | $8.76M | 22.08% | 5.33% | -14.71× | Reported |
| 2018-03-31 | $51.75M | (m) | $12.01M | $-129.99M | $6.42M | (m) | (m) | -20.25× | Reported |
| 2017-12-31 | $50.06M | $210.94M | $11.40M | $-134.03M | $4.21M | 23.73% | 5.41% | -31.81× | Reported |
| 2017-09-30 | $48.50M | $206.47M | $11.04M | $-126.82M | $2.03M | 23.49% | 5.35% | -62.54× | Reported |
| 2017-06-30 | $47.24M | $203.71M | $10.73M | $-128.44M | $697.00K | 23.19% | 5.27% | -184.27× | Reported |
| 2017-03-31 | $45.75M | $202.07M | $10.75M | $-123.91M | $601.00K | 22.64% | 5.32% | -206.18× | Reported |
| 2016-12-31 | $41.86M | $217.07M | $10.60M | $-96.49M | $533.00K | 19.28% | 4.88% | -181.03× | Reported |
| 2016-09-30 | $38.41M | $220.69M | $10.38M | $-76.12M | $497.00K | 17.40% | 4.71% | -153.16× | Reported |
| 2016-06-30 | $34.40M | $211.72M | $9.88M | $-70.21M | $1.53M | 16.25% | 4.67% | -45.92× | Reported |
| 2016-03-31 | $30.84M | $204.82M | $8.57M | $-63.17M | $2.61M | 15.06% | 4.19% | -24.20× | Reported |
| 2015-12-31 | $27.71M | $190.35M | $7.33M | $-59.84M | $3.50M | 14.56% | 3.85% | -17.07× | Reported |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $179.43M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $17.29M | $159.29M | $5.16M | $665.00K | $4.22M | 10.86% | 3.24% | 0.16× | Reported |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $11.55M | $55.17M | $1.66M | $-25.27M | $1.87M | 20.93% | 3.00% | -13.49× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QUEST DIAGNOSTICS INC (DGX) | United States | $26.096B | 22.09 |
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |